Based on the AC Immune Ltd stock forecast from 1 analysts, the average analyst target price for AC Immune Ltd is USD 16.00 over the next 12 months. AC Immune Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AC Immune Ltd is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, AC Immune Ltd’s stock price was USD 1.56. AC Immune Ltd’s stock price has changed by -6.02% over the past week, -32.76% over the past month and -43.07% over the last year.
No recent analyst target price found for AC Immune Ltd
No recent average analyst rating found for AC Immune Ltd
Company Overview AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Read Less
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are d...Read More
Frequently Asked Questions About AC Immune Ltd (ACIU) Stock
Based on ratings from 1 analysts AC Immune Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ACIU's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ACIU is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
ACIU stock's Price/Earning ratio is 11.63.
Our analysis grades ACIU stock's Price / Earning ratio at F. This means that ACIU stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACIU may be a overvalued for its sector.
The last closing price of ACIU's stock was USD 1.56.
The most recent market capitalization for ACIU is USD 0.21B.
Based on targets from 1 analysts, the average taret price for ACIU is projected at USD 16.00 over the next 12 months.
This means that ACIU's stock price may go up by +925.64% over the next 12 months.
We can't find any ETFs which contains AC Immune Ltd's stock.
As per our most recent records AC Immune Ltd has 133 Employees.
AC Immune Ltd's registered address is Building B, Lausanne, Switzerland, 1015.
You can get more information about it from AC Immune Ltd's website at https://www.acimmune.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About AC Immune Ltd (ACIU) Stock
Based on ratings from 1 analysts AC Immune Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ACIU's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ACIU is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
ACIU stock's Price/Earning ratio is 11.63.
Our analysis grades ACIU stock's Price / Earning ratio at F. This means that ACIU stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ACIU may be a overvalued for its sector.
The last closing price of ACIU's stock was USD 1.56.
The most recent market capitalization for ACIU is USD 0.21B.
Based on targets from 1 analysts, the average taret price for ACIU is projected at USD 16.00 over the next 12 months.
This means that ACIU's stock price may go up by +925.64% over the next 12 months.
We can't find any ETFs which contains AC Immune Ltd's stock.
As per our most recent records AC Immune Ltd has 133 Employees.
AC Immune Ltd's registered address is Building B, Lausanne, Switzerland, 1015.
You can get more information about it from AC Immune Ltd's website at https://www.acimmune.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACIU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
